Cytoreductive nephrectomy with thrombectomy before targeted therapy improves survival for metastatic renal cell carcinoma with venous tumor thrombus: a single-center experience

World Journal of Surgical Oncology

Research

Pengjie Wu¹  Xianghui Ning²  Jinchao Chen²  Teng Li²  Nienie Qi²  Kan Gong³  Jin Wang⁴ 

[1] Department of Urology, Beijing Hospital, Beijing, China;Department of Urology, Peking University First Hospital, Institute of Urology, Peking University, Beijing, China;Department of Urology, Peking University First Hospital, Institute of Urology, Peking University; National Urological Cancer Center, No. 8, Xishiku St., Xicheng Dist, 100034, Beijing, China;Department of cardiac surgery, Peking University First Hospital, Beijing, China;

关键词: Renal cell carcinoma;    Metastasis;    Venous tumor thrombus;    Cytoreductive surgery;    Targeted molecular therapy;   

DOI  :  10.1186/s12957-016-1066-3

 received in 2016-05-11, accepted in 2016-12-14,  发布年份 2017

来源: Springer

【 摘 要 】

BackgroundThe aim of the study is to evaluate the role of cytoreductive nephrectomy (CN) with thrombectomy before targeted molecular therapy (TMT) on survival in metastatic renal cell carcinoma (mRCC) with venous tumor thrombus.MethodsWe performed a retrospective analysis of 47 patients treated in our center from April 2008 to October 2014. In the study, 20 patients underwent CN with thrombectomy followed by targeted therapy (group 1); 15 patients received targeted therapy alone (group 2); and 12 patients underwent CN with thrombectomy alone (group 3). The overall survival (OS) and cancer-specific survival (CSS) were calculated according to the Kaplan-Meier survival curve method, and prognostic variables were assessed by Cox regression analyses.ResultsThe median follow-up times of group 1, group 2, and group 3 were 24.5, 12, and 6.5 months, respectively. During follow-up, in both group 1 and group 3, 12 patients died. In group 2, 14 patients died. The median OS of group 1, group 2, and group 3 was 22, 12, and 6 months, respectively (P < 0.001). Compared with surgery alone and targeted therapy alone, patients with cytoreductive surgery before targeted therapy had statistically better survival benefits (P < 0.001, P = 0.009, respectively). On univariate analysis, the number of metastatic sites (P = 0.004) was a statistically significant prognostic factor influencing OS.ConclusionsOur single-center experience showed that CN with thrombectomy before targeted therapy improved the survival of patients with mRCC with venous tumor thrombus. The number of metastatic sites was an independent prognostic factor influencing OS.

【 授权许可】

CC BY   
© The Author(s). 2017